These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: HIV-infected hemophiliacs reject drug companies' offer.
    Journal: AIDS Policy Law; 1996 May 31; 11(10):4. PubMed ID: 11363498.
    Abstract:
    Leaders of a group of HIV-infected hemophiliacs turned down a proposed $640 million settlement offered by four makers of blood-clotting products. The offer would have provided $120,000 to each person with hemophilia who was infected by contaminated clotting products. The leaders question why American hemophiliacs should settle for less money than the drug companies gave to Japanese hemophiliacs--about $420,000 plus monthly stipends for life to each of the 1,800 Japanese hemophiliacs who contracted HIV from clotting products. [Name removed], one of the plaintiffs, regards the offer as a starting point and will continue to negotiate. The companies involved in the settlement are Rhone-Poulenc Rorer of Collegeville, PA; Alpha Therapeutic Corp. of Los Angeles; Baxter Healthcare Corp. of Deerfield, IL; and Bayer Corp. of Germany. New evidence continues to emerge in the court proceedings. The Philadelphia Inquirer reported that the Food and Drug Administration (FDA) gave drug makers advance notice before conducting safety inspections at collection centers despite a warning from an enforcement official in 1982 that the policy allowed sloppy or corrupt plasma-collection centers to clean up and cover up. The memo was written 2 months before government scientists suggested that the agent that causes AIDS might be transmitted through plasma-based clotting products.
    [Abstract] [Full Text] [Related] [New Search]